Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
J&J gene therapy fails ph. 3 rare eye disease trial
The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa.
Darren Incorvaia
May 5, 2025 11:33am
HistoSonics considering a sale to major medtechs: report
May 2, 2025 11:30am
Next-gen pulsed field ablation comes to the fore at HRS
Apr 27, 2025 1:15pm
J&J calls time on Addex partnership a year after epilepsy fail
Apr 17, 2025 7:05am
J&J estimates $400M impact from tariffs, largely in medtech
Apr 15, 2025 2:00pm
J&J reports first cases with Ottava surgical robot
Apr 14, 2025 11:44am
